Gain Therapeutics Gets FDA Approval to Start Phase 2 Study of Parkinson's Drug
By Elias Schisgall
The Food and Drug Administration authorized Gain Therapeutics' investigational new drug application for a Parkinson's disease treatment, clearing the way for the biotechnology company to launch a phase 2 trial for the drug.
The application for the drug, known as GT-02287, was approved after phase 1 studies in Australia showed positive activity and safety data, the company said Monday.
The phase 2 study is expected to begin in the third quarter and include the initial study sites in Australia as well as new sites in the U.S. and Europe, the company said.
"The FDA's decision is a significant milestone for Gain and we believe it validates the extensive preclinical and clinical work supporting further development of GT-02287," Chief Executive Officer Gene Mack said.
Shares of Gain surged 21%, to $2.40, in after-hours trading Monday.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
June 29, 2026 16:54 ET (20:54 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
3 of the Best Dividend Stocks to Own
The 10 Best Companies to Invest in Now
This Once-Hot AI Stock Now Looks Deeply Undervalued
United States